Alentis Therapeutics
Alentis Therapeutics is a clinical-stage biotechnology company developing treatments for Claudin-1 positive (CLDN1+) tumors and organ fibrosis. They focus on creating first-in-class antibody-drug conjugates (ADCs) targeting CLDN1, a previously unexploited target in cancer treatment. Their approach aims to provide highly effective cancer treatments with less toxicity than traditional methods.
Buy Funded Startups lists
Funding Round: Series D
Funding Amount: $181.4M
Date: 12-Nov-2024
Investors: OrbiMed, Novo Holdings, Jeito Capital, Frazier Life Sciences, Longitude Capital, RA Capital, Catalio Capital, Piper Heartland Healthcare Capital, Avego Bioscience Capital, Morningside Venture Investments, BB Pureos, Bpifrance
Markets: Biotechnology, Oncology
HQ: Allschwil, Basel-Country, Switzerland
Founded: 2019
Website: https://alentis.ch/
LinkedIn: https://www.linkedin.com/company/alentis-therapeutics
Crunchbase: https://www.crunchbase.com/organization/alentis-therapeutics
Leave a Comment
Comments
No comments yet.